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Abstract: 
Introduction: Obestatin is a recently discovered peptide produced in the stomach, which was originally described to 
suppress food intake and decrease body weight in experimental animals. Objectives of the study: The basic objective 
of the study is to analyze the level of plasma obestatin levels in obesity among local population of Pakistan. 
Methodology of the study: This cross sectional study was conducted in Services Institute of Medical Sciences, Lahore 
during April 2018 till October 2018. The data was collected from 100 obese patients which was also suffering from 
heart and cholesterol diseases. The data was collected through a questionnaire which include all the socio-
demographic factors. Body mass index (BMI) and waist circumference (WC) were done for patients and controls as 
anthropometrical tests, while fasting serum glucose (FSG) measured using spectrophotometric technique. Each serum 
sample was analyzed for obestatin hormone and fasting insulin using enzyme linked immune sorbent assay (ELISA). 
Results: The data was collected from 100 participants.  Mean fasting obestatin levels was 0.450 ± 0.468 and 0.959 ± 
0.889 respectively in hypertensive and normotensive obese and the difference of mean fasting obestatin levels between 
the both groups was statistically significant with p value 0.000. Mean fasting blood cholesterol level was 206.42 ± 
44.420 and 202.39 ± 48.344 respectively in normal and obese and the difference was not statistically significant with 
p value 0.644. Conclusion: It is concluded that obestatin levels are directly correlated with blood glucose level. 
Furthermore, there was a clear relationship between obestatin and both BP and HOMA-IR, suggesting that obestatin 
might play a role in BP regulation. 
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INTRODUCTION: 
Obestatin is a recently discovered peptide produced in 
the stomach, which was originally described to 
suppress food intake and decrease body weight in 
experimental animals. We investigated fasting plasma 
obestatin levels in normal weight, obese and anorectic 
women and associations of plasma obestatin levels 
with anthropometric and hormonal parameters [1]. 
Hormonal (obestatin, ghrelin, leptin, insulin) and 
anthropometric parameters and body composition 
were examined in 15 normal weight, 21 obese and 15 
anorectic women. Fasting obestatin levels were 
significantly lower in obese than in normal weight and 
anorectic women, whereas ghrelin to obestatin ratio 
was increased in anorectic women [2]. Compared to 
leptin, only minor differences in plasma obestatin 
levels were observed in women who greatly differed 
in the amount of fat stores. Obesity is a pathological 
condition, which results from an imbalance between 
caloric intake and expenditure, and is characterized by 
excessive body fat accumulation, that has severe 
impact on life quality and life expectance due to the 
burden of associated co-morbidities. Recent data from 
the World Health Organization suggest that 11% of the 
world population (more than half a billion people) is 
obese, while 35% is overweighed [3].  
Obestatin is a 23-acid metabolic peptide, derived from 
the preproghrelin gene which was isolated first from 
the rat stomach in 2005. However, obestatin is also 
expressed in other GI organs (pancreas, liver), adipose 
tissue, skeletal muscle, lungs, thyroid and mammary 
glands and testes, suggesting a multifunctional role of 
it, which can act both centrally and peripherally [4]. It 
was originally described as a direct antagonist of 
ghrelin with anorexigenic effect. Both central and 
peripheral injection decreased food intake in a time 
and dose-dependent manner, body weight gain, and 
intestinal motility via the G-protein coupled receptor 
39 (GPR39) a member of the GHSR family which was 
rapidly refuted as a receptor for obestatin by several 
studies [5].  
Objectives of the study 
The basic objective of the study is to analyze the level 
of plasma obestatin levels in obesity among local 
population of Pakistan. 
METHODOLOGY OF THE STUDY: 
This cross sectional study was conducted in Services 
Institute of Medical Sciences, Lahore during April 
2018 till October 2018. The data was collected from 
100 obese patients which was also suffering from heart 
and cholesterol diseases. The data was collected 
through a questionnaire which include all the socio-
demographic factors. Body mass index (BMI) and 
waist circumference (WC) were done for patients and 
controls as anthropometrical tests, while fasting serum 
glucose (FSG) measured using spectrophotometric 
technique. Each serum sample was analyzed for 
obestatin hormone and fasting insulin using enzyme 
linked immune sorbent assay (ELISA). 
Statistical analysis 
The data was collected and analyzed using SPSS 
analysis. T- test was used in making a comparison of 
the two-tailed P value of the two groups with a 
significance set at p<0.05.  
RESULTS: 
The data was collected from 100 participants.  Mean 
fasting obestatin levels was 0.450 ± 0.468 and 0.959 ± 
0.889 respectively in hypertensive and normotensive 
obese and the difference of mean fasting obestatin 
levels between the both groups was statistically 
significant with p value 0.000. Mean fasting blood 
cholesterol level was 206.42 ± 44.420 and 202.39 ± 
48.344 respectively in normal and obese and the 
difference was not statistically significant with p value 
0.644. 
Table 01: Comparison of mean fasting obestatin levels between hypertensive and normotensive obese patients. 
Group n Mean Std. Deviation P Value 
Hypertensive obese 57 0.450 
0.468 
 
 0.000  
Normotensive obese 57 0.959 0.889 
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DISCUSSION: 
Obestatin is a recently discovered peptide produced in 
the stomach, which was originally described to 
suppress food intake and decrease body weight in 
experimental animals. We investigated fasting plasma 
obestatin levels in normal weight, obese and anorectic 
women and associations of plasma obestatin levels 
with anthropometric and hormonal parameters [6]. 
Hormones and neuropeptides control and integrate the 
neuro circuits of metabolism, thirst, thermoregulation, 
and sleep overlapping in the hypothalamus. 
Accordingly, besides its peripheral effects, central 
actions of obestatin were also identified [7]. To note 
first, when administered ICV this peptide inhibited 
thirst in fed and fasted male rats, and pretreatment with 
obestatin also neutralized the dipsogenic effect of 
angiotensin II. Furthermore, it was also suggested that 
the anorexigenic effect of this peptide is a 
consequence of the thirst inhibition, the so called 
dehydration anorexia [8]. 
Obesity has become a major public health problem 
throughout the world and at least one-third of Arabs 
are obese, and this figure is rising steadily despite 
increased interest in fitness. Excess fat accumulation 
promotes the development of insulin resistance, 
glucose intolerance and type 2 diabetes mellitus [9]. 
The increasing prevalence of obesity is a serious 
health concern. Obesity is known to be strongly 
associated with hypertension and other arteriosclerotic 
disease, but the pathogenic mechanisms linking 
hypertension and obesity have not been fully 
determined. The possible roles of obestatin and ghrelin 
in obesity and metabolic syndrome have been studied. 
Changes in the concentrations of these hormones, and 
in the ghrelin/obestatin ratio, may be risk factors for 
obesity and hypertension [10]. 
 
Obestatin levels were significantly reduced suggesting 
that the secretion of the Ghrelin and Obestatin is 
regulated in an opposing manner by the nutritional 
status. These findings suggest that obestatin could 
modulate endogenous Ghrelin actions, and have 
shown that obestatin may inhibit jejunal activity and 
may suppress gastric emptying activity [11].  
CONCLUSION: 
It is concluded that obestatin levels are directly 
correlated with blood glucose level. Furthermore, 
there was a clear relationship between obestatin and 
both BP and HOMA-IR, suggesting that obestatin 
might play a role in BP regulation. 
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